Literature DB >> 29266882

Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?

Francesco Muratore1, Tanaz A Kermani2, Cynthia S Crowson3, Matthew J Koster3, Eric L Matteson3, Carlo Salvarani1, Kenneth J Warrington3.   

Abstract

OBJECTIVE: To compare patients with large-vessel giant cell arteritis (LV-GCA) characterized by wall thickening, stenosis, and/or occlusion of subclavian arteries to those with subclavian dilatation.
METHODS: For the purposes of the present retrospective study, 2 different subsets of LV-GCA were identified and compared from an established cohort of patients with radiographic evidence of subclavian artery vasculitis secondary to GCA: LV-GCA with wall thickening, stenosis, and/or occlusion of subclavian arteries (Group 1), and LV-GCA with dilatation of subclavian arteries without wall thickening or stenotic changes (Group 2).
RESULTS: The study included 109 patients in Group 1 and 11 in Group 2. Large-vessel involvement secondary to GCA was diagnosed significantly later in patients from Group 2 compared to those from Group 1 (median 15.3 versus 0.0 months; P = 0.010). Compared to patients from Group 1, those from Group 2 were more frequently male (17% versus 45%; P = 0.027), ever smokers (42% versus 73%; P = 0.048), and more frequently had a history of coronary artery disease (11% versus 36%; P = 0.018). At LV-GCA diagnosis, 10 of the 11 patients (91%) from Group 2 had aortic dilatation compared to 13 of 109 patients (12%) from Group 1 (P < 0.001). During the followup period, the prevalence of aortic aneurysm was significantly higher in patients from Group 2 compared with those from Group 1 (64% versus 7% at 5 years; P < 0.001).
CONCLUSION: Two different subsets of LV-GCA were identified. Given the strong association between subclavian artery dilatation and aortic aneurysm, such patients should be evaluated and monitored carefully for aortic dilatation.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29266882     DOI: 10.1002/acr.23498

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  6 in total

1.  Large vessel vasculitis with rare presentation of acute rhabdomyolysis: A case report and review of literature.

Authors:  Lan-Jun Fu; Shou-Ci Hu; Wen Zhang; Li-Qing Ye; Hong-Bo Chen; Xiao-Jun Xiang
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

Review 2.  Diagnosis and differential diagnosis of large-vessel vasculitides.

Authors:  Gokhan Keser; Kenan Aksu
Journal:  Rheumatol Int       Date:  2018-09-17       Impact factor: 2.631

Review 3.  The Treatment of Giant Cell Arteritis in Different Clinical Settings.

Authors:  Alexander Pfeil; Peter Oelzner; Peter Hellmann
Journal:  Front Immunol       Date:  2019-01-24       Impact factor: 7.561

4.  Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event.

Authors:  Olivier Espitia; Gauthier Blonz; Geoffrey Urbanski; Cédric Landron; Jérôme Connault; Christian Lavigne; Pascal Roblot; François Maillot; Alexandra Audemard-Verger; Mathieu Artifoni; Cécile Durant; Béatrice Guyomarch; Mohamed Hamidou; Julie Magnant; Christian Agard
Journal:  Arthritis Res Ther       Date:  2021-01-07       Impact factor: 5.156

Review 5.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

6.  Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.

Authors:  Takahiko Sugihara; Hitoshi Hasegawa; Haruhito A Uchida; Hajime Yoshifuji; Yoshiko Watanabe; Eisuke Amiya; Yasuhiro Maejima; Masanori Konishi; Yohko Murakawa; Noriyoshi Ogawa; Shunsuke Furuta; Yasuhiro Katsumata; Yoshinori Komagata; Taio Naniwa; Takahiro Okazaki; Yoshiya Tanaka; Tsutomu Takeuchi; Yoshikazu Nakaoka; Yoshihiro Arimura; Masayoshi Harigai; Mitsuaki Isobe
Journal:  Arthritis Res Ther       Date:  2020-04-07       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.